CG Oncology Inc. has announced topline results from the BOND-003 Cohort P and initial findings from the CORE-008 Cohort A clinical trials evaluating cretostimogene grenadenorepvec in patients with non-muscle invasive bladder cancer (NMIBC). The results, presented at the Society of Urologic Oncology (SUO) 26th Annual Meeting, highlighted promising efficacy and a favorable safety profile for cretostimogene. In the BOND-003 Cohort P study involving patients with BCG-unresponsive (BCG-UR) papillary-only NMIBC, high-grade event-free survival (HG-EFS) rates at 3, 6, and 9 months were reported at 95.7%, 84.6%, and 80.4%, respectively. No Grade 3 or higher treatment-related adverse events or deaths were observed, and no patients required radical cystectomy or progressed to muscle invasive bladder cancer. The CORE-008 Cohort A data in high-risk BCG-naïve NMIBC demonstrated an 88% complete response rate and a favorable safety profile with optimized administration. Enrollment has been completed for the BOND-003 Cohort P study, with 56 patients receiving cretostimogene.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9597510-en) on December 05, 2025, and is solely responsible for the information contained therein.
Comments